Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18

Increases in administration and corporate costs are probably due to the acquisition of the lease that was included as part of the azer-cel licensing agreement.
From that earlier announcement on azer-cel licensing.
"Imugene will also acquire the lease to a state-of-the art 32,800 sq feet GMP manufacturing facility in North Carolina, drug material for completion of a Phase 1b clinical trial and a highly experienced cell therapy and manufacturing team of approximately 50 personnel."

The above is also confirmed in the 4C with the following:
"Imugene's azer-cel clinical drug is supplied from the company’s state-of-the-art manufacturing facility in North Carolina."

The current 4C probably reflects the full effects of the costs of acquiring that lease.
Given that Azer-cel was acquired in late August, the prior 4C only partially reflected the running costs of this facility.